In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Aortic stiffness is significantly associated with left ventricular mass in females but not in males: insights from the CORINTHIA study

Session Poster Session 4

Speaker Evangelos Oikonomou

Event : ESC Congress 2019

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardiovascular Disease in Women
  • Session type : Poster Session

Authors : T Papaioannou (Athens,GR), E Oikonomou (Athens,GR), G Lazaros (Athens,GR), E Christoforatou (Athens,GR), G Vogiatzi (Athens,GR), S Tsalamandris (Athens,GR), C Chasikidis (Athens,GR), A Kalambogias (Athens,GR), V-X Mystakidi (Athens,GR), N Galiatsatos (Athens,GR), M Santouri (Athens,GR), G Latsios (Athens,GR), S Deftereos (Athens,GR), D Tousoulis (Athens,GR)

T. Papaioannou1 , E. Oikonomou1 , G. Lazaros1 , E. Christoforatou1 , G. Vogiatzi1 , S. Tsalamandris1 , C. Chasikidis1 , A. Kalambogias1 , V.-X. Mystakidi1 , N. Galiatsatos1 , M. Santouri1 , G. Latsios1 , S. Deftereos2 , D. Tousoulis2 , 1National & Kapodistrian University of Athens, First Department of Cardiology, Hippokration Hospital, Medical School - Athens - Greece , 2National & Kapodistrian University of Athens, Second Department of Cardiology - Athens - Greece ,

European Heart Journal ( 2019 ) 40 ( Supplement ), 2069

Introduction: Arterial stiffening may contribute to the increase of left ventricular mass (LVM) and the development of left ventricular hypertrophy (LVH). Although male gender has been also found to be an independent determinant of LVH, it is unknown if the adverse effect of increased aortic stiffening on LVM differs between males and females.

Aim: To evaluate the association of aortic stiffness as assessed by carotid-to-femoral pulse wave velocity (cf-PWV) with LVM and LVH in a general population and compare these associations between males and females.

Methods: Demographic, laboratory and clinical data of 1686 subjects (693 males and 993 females) from the cross-sectional, observational study “Corinthia” were analyzed. All subjects underwent applanation tonometry and pulse wave analysis for the measurement of cf-PWV and echocardiography examination for the computation of LVM which was adjusted by body surface area providing the LVM index (LVMI). Multivariate linear regression analysis was performed for the determination of independent factors related with LVMI. Receiver operator curve analysis (ROC) was used to compare the ability of cf-PWV to predict LVH, in males and females separately.

Results: In the female population, significant and independent determinants of LVMI were: age (beta=0.243, p<0.001), urea (beta=0.119, p=0.001), hypertension (beta=0.089, p=0.028) and cf-PWV (beta=0.096, p=0.021). In contrast, in the male population, LVMI was independently related with age (beta=0.242, p<0.001), systolic blood pressure (beta=0.095, p=0.027), LDL (beta=-0.087, p=0.047) and creatinine (beta=0.092, p=0.031). ROC analysis showed that cf-PWV is a stronger predictor of LVH in females than in males (figure).

Conclusion: Increased aortic stiffness measured by cf-PWV is significantly related with increased LVMI regardless from age and other risk factors only in females. Moreover cf-PWV was a stronger predictor of left-ventricular hypertrophy in females than males. These findings should be further explored in prospective studies.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are